e-ISSN: 2320-4230, p-ISSN: 2961-6085

Journal of Drug Discovery and Therapeutics

Available Online at www.jddt.in

CODEN: - JDDTBP (Source: - American Chemical Society)

Volume 13, Issue 6; 2025, 15-18

Hybrid-Responsive Contact Lenses for Precision Eye Care

Amit Choudhary[1], Divyansh Khandal[1], Md Ajaz Alam[2], Pawan Kumar Basniwal[3]

[1]Scholars, Sri Balaji College of Pharmacy, Jaipur
[2]Assistant Professor, Sri Balaji College of Pharmacy, Jaipur
[3]Professor & Principal, Sri Balaji College of Pharmacy, Jaipur

Received: 19-08-2025 / Revised: 18-09-2025 / Accepted: 20-10-2025
Corresponding author: Md Ajaz Alam
Conflict of interest: No conflict of interest.

Abstract:

Hybrid responsive contact lenses represent an emerging innovation in ocular drug delivery and diagnostic technology. By combining stimuli-responsive polymers, nanocarriers, and biosensing systems, these lenses offer targeted and controlled therapeutic release in response to physiological changes such as pH, temperature, or tear composition. This intelligent responsiveness ensures precise drug dosing, enhanced bioavailability, and reduced systemic side effects compared to conventional eye drops or inserts. Furthermore, integration of micro-sensors enables real-time monitoring of ocular parameters like intraocular pressure and tear biomarkers, facilitating early detection and personalized treatment of eye disorders such as glaucoma, dry eye syndrome, and diabetic retinopathy. Although challenges remain regarding biocompatibility, long-term stability, and large-scale production, hybrid responsive contact lenses hold immense potential to revolutionize precision eye care and advance the future of ophthalmic therapy.

Keywords: Hybrid contact lenses, Stimuli-responsive polymers, Smart contact lenses, Controlled drug delivery, Ocular therapeutics, Precision eye care, Biosensing technology, Nanocarriers,Tear fluid biomarkers, Glaucoma management

Introduction

According to the World Health Organization, at least 2.2 billion people worldwide suffer from some form of vision impairment, with a significant proportion caused by preventable or treatable conditions such as glaucoma, dry eye syndrome, keratitis, and post-surgical inflammation.

Ophthalmic drugs used for the treatment of various ocular diseases are commonly administered by eye drops. However, due to anatomical and physiological factors, there is a low bioavailability of the active principle. In order to maintain adequate therapeutic levels for a longer period of time, innovative ophthalmic drug delivery systems have recently been proposed to overcome the limitations associated with conventional formulations.

The incorporation of the drug into the lens matrix favors a prolonged release of the active principle towards the post-lens tear film in contact with the cornea, where the drug has to penetrate. Contact lenses have emerged as promising platforms for improving ocular drug delivery. By increasing the contact time between the drug and the corneal surface, reducing wash out

by tears, and providing more controlled release, drug-loaded contact lenses can enhance bioavailability, reduce dosing frequency, and improve therapeutic outcomes.[1]

Anatomy of the eye and barriers to ocular drug delivery

The eye is a highly specialized organ with complex anatomy designed to protect vision, but this also makes drug delivery challenging. Drug delivery to the posterior segment of the eye is important for potentially treating various disorders in retina, choroid, vitreous humor and optic nerve.

Due to anatomic membrane barriers and the lacrimal drainage it can be quite challenging to obtain therapeutic drug concentrations in the posterior parts of the eye after topical drug administration.

Eye Anatomy (Relevant to Drug Delivery)

- Anterior segment: consists of the cornea, conjunctiva, aqueous humour, iris, ciliary body, and lens. Many topical ocular therapeutics are meant to act on or pass through these structures.[2]
- Posterior segment: includes vitreous humour, retina, choroid, sclera, and optic nerve. More difficult to reach via topical or systemic routes due to multiple barriers.[3]

Other Dynamic / Physiological Barriers

Blinking: physically removes drug from ocular surface.[4]

Enzymatic Barriers / Efflux Transporters: enzymes in tear film or ocular tissues degrade drugs; efflux pumps remove drugs from cells.[5]

Evolution of Contact Lenses in Pharmaceutical Drug Delivery

Initially, contact lenses were designed purely for vision correction, with no therapeutic purpose. However, researchers soon recognized that the close and prolonged contact of a lens with the corneal surface could serve as an effective drug reservoir, offering a way to overcome the poor bioavailability of conventional eye drops.

Conventional Drug-Loaded Lenses: Soak & Diffusion Methods

Soaking (dip-coating): The simplest method. A pre-manufactured soft contact lens (often made of hydrogel) is immersed in a solution of the drug. The drug diffuses into the lens matrix (into the water/hydrogel phase) via concentration gradient. Once placed on the eye, drug diffuses out into the tear film.[6]

Diffusion-driven release: After loading, drug release from the lens back into the ocular environment occurs by diffusion. The rate depends on properties of drug, lens material (water content, crosslinking, thickness), and external conditions (tear flow, blinking).[7]

Advantages

Very simple to do; uses commercially available lenses or standard hydrogel polymers.[6]

Limitations / Challenges

Initial burst release: A large fraction of the loaded drug is released quickly early on, rather than a steady sustained release.[6]

The main objectives for the development of DCR (drug-controlled release) based on SCLs (soft contact lenses) are [5]:

- To increase the drug delivery efficiency;
- To improve patient compliance and reduce undesirable systemic side effects, especially in chronic diseases such as glaucoma and dry eye

Drug Loading / Incorporation Strategies with Stimuli Responsiveness ● Soaking / Dip-coating

How the drug is loaded / held: - Immersion of lens / hydrogel in drug solution; drug diffuses into polymer network; sometimes with stimulus-sensitive groups in the polymer.

Stimulus used (trigger):- pH / ionic strength / temperature (if polymer has responsive groups).

Example(s):- pHEMA lenses with ionic comonomers (vinylpyrrolidone, NIPAAm etc.) exhibited pH-sensitive release: release increases / decreases with pH depending on lens composition.[8]

Advantages: - Simple, easy to perform; can use commercial lenses; minimal additional fabrication complexity.

Challenges / Limitations: - High initial burst release; limited control over release duration; storage/pre-release leakage; limited drug loading, especially for hydrophobic drugs. Also changing lens properties (optical, mechanical) is possible.

Incorporation of Nanoparticles / Nanogels

How the drug is loaded / held: - Drugs are encapsulated in nano-carriers (polymeric NPs, liposomes, nanogels) which are then embedded inside the lens matrix (or sometimes surface). These carriers can themselves be stimuli-sensitive.

Stimulus used (trigger):- Temperature, pH, etc.

Example(s):- The "Stimulus-Responsive Contact Lens for IOP Measurement or Temperature-Triggered Drug Release" study: timolol loaded in thermosensitive PNIPAM nanogels embedded in nanoporous lens; release triggered by body temperature, sustained over days.[9]

Advantages: - Better control over release; reduced burst; ability to adjust responsiveness via the nanocarrier design; can enable "on-demand" release; can preserve lens optical properties if done well.

Challenges / Limitations :- Complexity of fabrication; ensuring uniform dispersion; ensuring carrier retention inside lens; possible impact on transparency, oxygen permeability, comfort; stability of carriers; regulatory challenges.

Future prospects

Stimuli-responsive contact lenses (SRCLs) are moving from proof-of-concept hydrogel/nanoparticle demonstrations toward integrated, on-demand therapeutic wearables that combine sensor feedback, microreservoirs/microfluidics and triggered release (light, temperature, pH, magnetic, electric, ultrasound).

Improved material systems: thermoresponsive and pH-responsive hydrogels and drug loaded nanogels embedded in conventional lens matrices to give longer, more predictable release profiles compared with eye drops.[10]

On-demand release via external triggers (light, magnetic fields, ultrasound) or internal biomarkers (inflammation markers, glucose) integrated with simple electronics or photo responsive chemistries. This enables dosing that responds to disease state rather than fixed schedules.[11]

Fully integrated therapeutic wearables: wireless telemetry, multi-drug reservoirs, and precision microfluidic pumps enabling complex regimens (e.g., glaucoma combination therapy), potentially reducing the need for repeat injections for some posterior problems using targeted release strategies. Regulatory approval and human trials will determine pace.[12]

Conclusion: Stimuli-responsive contact lenses offer a novel and highly promising approach for ocular drug delivery by providing controlled, sustained, and on-

demand release of therapeutic agents directly to the eye.

Advantages include higher ocular bioavailability, reduced dosing frequency, improved patient compliance, localized drug action with minimal systemic side effects, and the possibility of tailoring drug release according to patient needs through pH, temperature, enzyme, light, or magnetic responsiveness.

With advancements in smart polymers, nanocarrier technology, and microelectronics, SRCLs have the potential to revolutionize ocular therapy by reducing the need for frequent dosing or invasive procedures, improving treatment outcomes for chronic eye diseases like glaucoma, keratitis, and dry eye syndrome, and enhancing overall patient quality of life.

References

1. Iwona Rykowska, Iwona Nowak, Rafal Nowak (2021 Sep. 14) in PubMed "Soft Contact Lenses as Drug Delivery Systems: A Review".
2. Li-Ching Liu, Yi-Hao Chen, Da-Wen Lu (13 Nov. 2023) in Scholarly community Encyclopedia "Anatomy and Barriers of Ocular Drug Delivery"
3. Sudharshan Hariharan, Nilay R. Thakkar, Ashim K. Mitra (May/ June 2009) in Retina Today "Transporter-targeted Drug Delivery to the Retina"
4. Shiding Li, Liangbo Chen, Yao Fu (22 Jul. 2023) in Journal of Nanobiotechnology "Nanotechnology-based ocular drug delivery systems: recent advances and future prospects".
5. Rinda Devi Bachu, Pallabitha Chowdhary, Zharaa H F Al-Saedi, Pradeep K Karla, Sai H S Boddu (2018 Feb. 27) in PubMed "Central Ocular Drug Delivery Barriers—Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases"
6. Xin Wen, Qingping Liu, Mingzhi Zhang (23 May 2023) in Wiley Online Library "Innovative advancement of contact lenses for noninvasive diagnosis and therapy: A mini review".
7. Daniel M. Anderson, Rayanne A. Luke (24 Sep. 2024) in Springer Nature "Mathematical models of drug delivery via a contact lens during wear".
8. Pharma excipients (31 oct. 2024) "Selected drug delivery with contact lenses"
9. Se-Hee Lee, Kyung-Sik shin, Jae- woo kim, Ji-yoon kang,Jong-ki kim (2020 mar. 9) in PubMed central "Stimulus responsive contact lens for IOP measurement or temperature triggered drug release"
10. Aravind M, Ankur Saxena, Dhaneshwar Mishra, Kulwant Singh, Sajan D. George (3 Apr. 2025) in Microsystems & Nanoengineering "Microfluidic contact lens: fabrication approaches and applications"
11. Shuting Xu, Yaming Zhang, Jia Li, Xinyu Zhang, Weiping Wang (2025 Mar.24) in PubMed Central "External stimuli-responsive drug delivery to the posterior segment of the eye"
12. Aravind M, Ankur Saxena, Dhaneshwar Mishra, Kulwant Singh, Sajan D. George (3 Apr. 2025) in Microsystems & Nanoengineering "Microfluidic contact lens: fabrication approaches and applications"